Annual CFF
$625.00 K
+$2.56 M+132.38%
31 December 2023
Summary:
Theriva Biologics annual cash flow from financing activities is currently $625.00 thousand, with the most recent change of +$2.56 million (+132.38%) on 31 December 2023. During the last 3 years, it has fallen by -$2.73 million (-81.39%). TOVX annual CFF is now -99.16% below its all-time high of $74.00 million, reached on 31 December 2021.TOVX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$3.72 M
+$1.94 M+109.59%
01 September 2024
Summary:
Theriva Biologics quarterly cash flow from financing activities is currently $3.72 million, with the most recent change of +$1.94 million (+109.59%) on 01 September 2024. Over the past year, it has increased by +$3.71 million (+371500.00%). TOVX quarterly CFF is now -94.98% below its all-time high of $74.00 million, reached on 01 March 2021.TOVX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$4.03 M
+$3.71 M+1171.92%
01 September 2024
Summary:
Theriva Biologics TTM cash flow from financing activities is currently $4.03 million, with the most recent change of +$3.71 million (+1171.92%) on 01 September 2024. Over the past year, it has increased by +$5.24 million (+434.33%). TOVX TTM CFF is now -94.79% below its all-time high of $77.36 million, reached on 01 March 2021.TOVX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TOVX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +132.4% | +10000.0% | +434.3% |
| 3 y3 years | -81.4% | +100.0% | -94.5% |
| 5 y5 years | +100.0% | +100.0% | +100.0% |
TOVX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.2% | +132.4% | at high | +213.0% | -94.5% | +308.9% |
| 5 y | 5 years | -99.2% | +132.4% | -95.0% | +213.0% | -94.8% | +308.9% |
| alltime | all time | -99.2% | +132.4% | -95.0% | +120.7% | -94.8% | +135.3% |
Theriva Biologics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.72 M(+109.6%) | $4.03 M(+1171.9%) |
| June 2024 | - | $1.77 M(>+9900.0%) | $317.00 K(-53.4%) |
| Mar 2024 | - | $0.00(-100.0%) | $680.00 K(+8.8%) |
| Dec 2023 | $625.00 K(-132.4%) | -$1.46 M(<-9900.0%) | $625.00 K(-151.8%) |
| Sept 2023 | - | $1000.00(-100.0%) | -$1.21 M(-179.0%) |
| June 2023 | - | $2.14 M(-3983.6%) | $1.53 M(-350.7%) |
| Mar 2023 | - | -$55.00 K(-98.3%) | -$609.00 K(-68.4%) |
| Dec 2022 | -$1.93 M(-102.6%) | -$3.29 M(-220.3%) | -$1.93 M(-242.1%) |
| Sept 2022 | - | $2.73 M(>+9900.0%) | $1.36 M(-198.7%) |
| June 2022 | - | $0.00(-100.0%) | -$1.38 M(0.0%) |
| Mar 2022 | - | -$1.38 M(<-9900.0%) | -$1.38 M(-101.9%) |
| Dec 2021 | $74.00 M(+2103.1%) | - | - |
| Dec 2021 | - | $0.00(0.0%) | $74.00 M(-4.3%) |
| Sept 2021 | - | $0.00(0.0%) | $77.36 M(0.0%) |
| June 2021 | - | $0.00(-100.0%) | $77.36 M(0.0%) |
| Mar 2021 | - | $74.00 M(+2103.1%) | $77.36 M(+2203.1%) |
| Dec 2020 | $3.36 M(>+9900.0%) | $3.36 M(>+9900.0%) | $3.36 M(>+9900.0%) |
| Sept 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2019 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2019 | - | $0.00(0.0%) | $22.67 M(-21.0%) |
| June 2019 | - | $0.00(0.0%) | $28.69 M(-1.4%) |
| Mar 2019 | - | $0.00(-100.0%) | $29.09 M(0.0%) |
| Dec 2018 | $29.09 M(+57.4%) | $22.67 M(+276.4%) | $29.09 M(+352.9%) |
| Sept 2018 | - | $6.02 M(+1405.5%) | $6.42 M(-49.8%) |
| June 2018 | - | $400.00 K(>+9900.0%) | $12.80 M(-29.1%) |
| Mar 2018 | - | $0.00(-100.0%) | $18.04 M(-2.4%) |
| Dec 2017 | $18.48 M(-30.8%) | $1000.00(-100.0%) | $18.48 M(-57.8%) |
| Sept 2017 | - | $12.40 M(+119.6%) | $43.74 M(+36.8%) |
| June 2017 | - | $5.64 M(+1197.7%) | $31.98 M(+17.8%) |
| Mar 2017 | - | $435.00 K(-98.3%) | $27.14 M(+1.6%) |
| Dec 2016 | $26.71 M(-37.4%) | $25.26 M(+3865.5%) | $26.71 M(+1713.1%) |
| Sept 2016 | - | $637.00 K(-21.4%) | $1.47 M(-96.6%) |
| June 2016 | - | $810.00 K(>+9900.0%) | $43.49 M(+1.9%) |
| Mar 2016 | - | $0.00(-100.0%) | $42.68 M(0.0%) |
| Dec 2015 | $42.68 M(+124.3%) | $26.00 K(-99.9%) | $42.68 M(-30.8%) |
| Sept 2015 | - | $42.66 M(>+9900.0%) | $61.68 M(+224.2%) |
| June 2015 | - | $1000.00(-100.0%) | $19.02 M(-0.0%) |
| Dec 2014 | $19.03 M(+53.1%) | $19.02 M(>+9900.0%) | $19.03 M(+56.0%) |
| Sept 2014 | - | $0.00(0.0%) | $12.20 M(0.0%) |
| June 2014 | - | $0.00(-100.0%) | $12.20 M(0.0%) |
| Mar 2014 | - | $4000.00(-100.0%) | $12.20 M(-1.8%) |
| Dec 2013 | $12.43 M(+1.8%) | $12.20 M(>+9900.0%) | $12.43 M(+19.7%) |
| Sept 2013 | - | $0.00(0.0%) | $10.38 M(-0.9%) |
| June 2013 | - | $0.00(-100.0%) | $10.48 M(-3.8%) |
| Mar 2013 | - | $231.00 K(-97.7%) | $10.89 M(-10.7%) |
| Dec 2012 | $12.20 M(+74.8%) | $10.15 M(>+9900.0%) | $12.20 M(+492.6%) |
| Sept 2012 | - | $94.00 K(-77.4%) | $2.06 M(+4.8%) |
| June 2012 | - | $416.00 K(-73.0%) | $1.97 M(-59.1%) |
| Mar 2012 | - | $1.54 M(>+9900.0%) | $4.81 M(-31.1%) |
| Dec 2011 | $6.98 M(+588.3%) | $10.00 K(>+9900.0%) | $6.98 M(-0.1%) |
| Sept 2011 | - | $0.00(-100.0%) | $6.99 M(-11.6%) |
| June 2011 | - | $3.26 M(-12.3%) | $7.90 M(+69.3%) |
| Mar 2011 | - | $3.71 M(>+9900.0%) | $4.67 M(+360.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | $1.01 M(-2115.9%) | $18.30 K(-98.0%) | $1.01 M(+8.4%) |
| Sept 2010 | - | $915.10 K(+4237.0%) | $935.60 K(+2987.8%) |
| June 2010 | - | $21.10 K(-64.5%) | $30.30 K(+229.3%) |
| Mar 2010 | - | $59.50 K(-199.0%) | $9200.00(-118.3%) |
| Dec 2009 | -$50.30 K(-94.4%) | -$60.10 K(-713.3%) | -$50.30 K(-613.3%) |
| Sept 2009 | - | $9800.00(>+9900.0%) | $9800.00(+880.0%) |
| June 2009 | - | $0.00(0.0%) | $1000.00(-50.0%) |
| Mar 2009 | - | $0.00(0.0%) | $2000.00(-100.2%) |
| Dec 2008 | -$895.60 K(-111.4%) | $0.00(-100.0%) | -$895.60 K(-115.7%) |
| Sept 2008 | - | $1000.00(0.0%) | $5.69 M(-11.1%) |
| June 2008 | - | $1000.00(-100.1%) | $6.40 M(+0.5%) |
| Mar 2008 | - | -$897.60 K(-113.6%) | $6.38 M(-19.0%) |
| Dec 2007 | $7.87 M(-44.2%) | $6.59 M(+827.1%) | $7.87 M(-45.0%) |
| Sept 2007 | - | $710.80 K(-2638.6%) | $14.31 M(+1.5%) |
| June 2007 | - | -$28.00 K(-104.7%) | $14.10 M(-2.3%) |
| Mar 2007 | - | $600.00 K(-95.4%) | $14.43 M(+2.3%) |
| Dec 2006 | $14.11 M(+531.4%) | $13.03 M(+2506.2%) | $14.11 M(+1206.2%) |
| Sept 2006 | - | $500.00 K(+66.7%) | $1.08 M(+86.2%) |
| June 2006 | - | $300.00 K(+7.0%) | $580.30 K(+107.0%) |
| Mar 2006 | - | $280.30 K(-14.9%) | $280.30 K(-92.6%) |
| Dec 2005 | $2.23 M(-59.2%) | - | - |
| Mar 2003 | - | $329.20 K(-33.9%) | $3.79 M(-30.8%) |
| Dec 2002 | $5.47 M(-6.2%) | $497.70 K(+5.3%) | $5.47 M(-14.8%) |
| Sept 2002 | - | $472.80 K(-81.0%) | $6.42 M(-28.6%) |
| June 2002 | - | $2.49 M(+23.5%) | $9.00 M(-178.9%) |
| Mar 2002 | - | $2.02 M(+39.3%) | -$11.41 M(-295.5%) |
| Dec 2001 | $5.84 M(+30.2%) | $1.45 M(-52.5%) | $5.84 M(-11.6%) |
| Sept 2001 | - | $3.05 M(-117.0%) | $6.60 M(+44.4%) |
| June 2001 | - | -$17.92 M(-193.0%) | $4.57 M(-79.5%) |
| Mar 2001 | - | $19.26 M(+769.9%) | $22.27 M(+397.1%) |
| Dec 2000 | $4.48 M(-74.7%) | $2.21 M(+117.8%) | $4.48 M(-75.6%) |
| Sept 2000 | - | $1.02 M(-567.8%) | $18.35 M(-0.5%) |
| June 2000 | - | -$217.30 K(-114.8%) | $18.44 M(-0.9%) |
| Mar 2000 | - | $1.47 M(-90.9%) | $18.61 M(+5.2%) |
| Dec 1999 | $17.69 M(-14.5%) | $16.09 M(+1362.6%) | $17.69 M(+704.0%) |
| Sept 1999 | - | $1.10 M(-2358.7%) | $2.20 M(+633.3%) |
| June 1999 | - | -$48.70 K(-108.9%) | $300.00 K(-98.6%) |
| Mar 1999 | - | $548.70 K(-8.6%) | $21.25 M(+2.7%) |
| Dec 1998 | $20.70 M(+314.0%) | $600.00 K(-175.0%) | $20.70 M(+2.0%) |
| Sept 1998 | - | -$800.00 K(-103.8%) | $20.30 M(-10.6%) |
| June 1998 | - | $20.90 M(>+9900.0%) | $22.70 M(+354.0%) |
| Dec 1997 | $5.00 M(-21.9%) | $200.00 K(-87.5%) | $5.00 M(+4.2%) |
| Sept 1997 | - | $1.60 M(>+9900.0%) | $4.80 M(+50.0%) |
| June 1997 | - | $0.00(-100.0%) | $3.20 M(-58.4%) |
| Mar 1997 | - | $3.20 M(>+9900.0%) | $7.70 M(+20.3%) |
| Dec 1996 | $6.40 M(-31.2%) | $0.00(0.0%) | $6.40 M(0.0%) |
| Sept 1996 | - | $0.00(-100.0%) | $6.40 M(0.0%) |
| June 1996 | - | $4.50 M(+136.8%) | $6.40 M(+236.8%) |
| Mar 1996 | - | $1.90 M(-38.7%) | $1.90 M(-40.6%) |
| Dec 1995 | $9.30 M(+190.6%) | - | - |
| Dec 1994 | $3.20 M(-36.0%) | - | - |
| Mar 1994 | - | $3.10 M(-247.6%) | $3.20 M(-36.0%) |
| Dec 1993 | $5.00 M | -$2.10 M(-200.0%) | $5.00 M(-29.6%) |
| Sept 1993 | - | $2.10 M(+2000.0%) | $7.10 M(+42.0%) |
| June 1993 | - | $100.00 K(-98.0%) | $5.00 M(+2.0%) |
| Mar 1993 | - | $4.90 M | $4.90 M |
FAQ
- What is Theriva Biologics annual cash flow from financing activities?
- What is the all time high annual CFF for Theriva Biologics?
- What is Theriva Biologics annual CFF year-on-year change?
- What is Theriva Biologics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Theriva Biologics?
- What is Theriva Biologics quarterly CFF year-on-year change?
- What is Theriva Biologics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Theriva Biologics?
- What is Theriva Biologics TTM CFF year-on-year change?
What is Theriva Biologics annual cash flow from financing activities?
The current annual CFF of TOVX is $625.00 K
What is the all time high annual CFF for Theriva Biologics?
Theriva Biologics all-time high annual cash flow from financing activities is $74.00 M
What is Theriva Biologics annual CFF year-on-year change?
Over the past year, TOVX annual cash flow from financing activities has changed by +$2.56 M (+132.38%)
What is Theriva Biologics quarterly cash flow from financing activities?
The current quarterly CFF of TOVX is $3.72 M
What is the all time high quarterly CFF for Theriva Biologics?
Theriva Biologics all-time high quarterly cash flow from financing activities is $74.00 M
What is Theriva Biologics quarterly CFF year-on-year change?
Over the past year, TOVX quarterly cash flow from financing activities has changed by +$3.71 M (+371500.00%)
What is Theriva Biologics TTM cash flow from financing activities?
The current TTM CFF of TOVX is $4.03 M
What is the all time high TTM CFF for Theriva Biologics?
Theriva Biologics all-time high TTM cash flow from financing activities is $77.36 M
What is Theriva Biologics TTM CFF year-on-year change?
Over the past year, TOVX TTM cash flow from financing activities has changed by +$5.24 M (+434.33%)